{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:57:00Z","timestamp":1790485020463,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,6,18]]},"DOI":"10.1038\/onc.2014.264","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T10:28:36Z","timestamp":1408357716000},"page":"3315-3324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells"],"prefix":"10.1038","volume":"34","author":[{"given":"Q","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"BFonc2014264_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609\u2013615.","journal-title":"Nature"},{"key":"BFonc2014264_CR2","first-page":"3223","volume":"26","author":"MM Janat-Amsbury","year":"2006","unstructured":"Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 2006; 26: 3223\u20133228.","journal-title":"Anticancer Res"},{"key":"BFonc2014264_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1593\/neo.06658","volume":"9","author":"NA Said","year":"2007","unstructured":"Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 2007; 9: 23\u201335.","journal-title":"Neoplasia"},{"key":"BFonc2014264_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585\u2013591.","journal-title":"Carcinogenesis"},{"key":"BFonc2014264_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ijc.23963","volume":"124","author":"I Sher","year":"2009","unstructured":"Sher I, Adham SA, Petrik J, Coomber BL Autocrine VEGF-A\/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009; 124: 553\u2013561.","journal-title":"Int J Cancer"},{"key":"BFonc2014264_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.bcp.2008.07.023","volume":"76","author":"P Chiarugi","year":"2008","unstructured":"Chiarugi P, Giannoni E . Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008; 76: 1352\u20131364.","journal-title":"Biochem Pharmacol"},{"key":"BFonc2014264_CR7","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1242\/jcs.072165","volume":"124","author":"MC Guadamillas","year":"2011","unstructured":"Guadamillas MC, Cerezo A, Del Pozo MA Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci 2011; 124: 3189\u20133197.","journal-title":"J Cell Sci"},{"key":"BFonc2014264_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature08268","volume":"461","author":"ZT Schafer","year":"2009","unstructured":"Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109\u2013113.","journal-title":"Nature"},{"key":"BFonc2014264_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297\u2013308.","journal-title":"Cancer Cell"},{"key":"BFonc2014264_CR10","doi-asserted-by":"publisher","first-page":"e85576","DOI":"10.1371\/journal.pone.0085576","volume":"9","author":"WK Miskimins","year":"2014","unstructured":"Miskimins WK, Ahn HJ, Kim JY, Ryu S, Jung YS, Choi JY Synergistic anti-cancer effect of phenformin and oxamate. PLoS ONE 2014; 9: e85576.","journal-title":"PLoS ONE"},{"key":"BFonc2014264_CR11","first-page":"891","volume":"53","author":"D Yu","year":"1993","unstructured":"Yu D, Wolf JK, Scanlon M, Price JE, Hung MC Enhanced c-erbB-2\/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993; 53: 891\u2013898.","journal-title":"Cancer Res"},{"key":"BFonc2014264_CR12","first-page":"3994","volume":"46","author":"R Baumal","year":"1986","unstructured":"Baumal R, Law J, Buick RN, Kahn H, Yeger H, Sheldon K et al. Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line. Cancer Res 1986; 46: 3994\u20134000.","journal-title":"Cancer Res"},{"key":"BFonc2014264_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 2013; 3: 256.","journal-title":"Front Oncol"},{"key":"BFonc2014264_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10585-012-9562-5","volume":"30","author":"KK Ward","year":"2013","unstructured":"Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis 2013; 30: 579\u2013594.","journal-title":"Clin Exp Metastasis"},{"key":"BFonc2014264_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1535-7163.MCT-08-1106","volume":"8","author":"H Li","year":"2009","unstructured":"Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis\/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 2009; 8: 1692\u20131701.","journal-title":"Mol Cancer Ther"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2014264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014264","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:09:28Z","timestamp":1647893368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2014264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":15,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2015,6,18]]}},"alternative-id":["BFonc2014264"],"URL":"https:\/\/doi.org\/10.1038\/onc.2014.264","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]},"assertion":[{"value":"22 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}